|
|
 |
|
Viewing report
|
|
|
|
Controlled Release Cardiovascular Therapeutics: Drugs, Indications, Markets and Prospects
Greystone Associates, Aug 2011
The prevalence and incidence of cardiovascular conditions in developed economies continue to increase, creating challenges and opportunities for cardiovascular drug developers. While the vast majority of drugs for treating cardiovascular conditions are oral immediate release products, issues related to drug safety and patient compliance have focused attention on formulations that can improve drug safety profiles and reduce dosing frequency. Important treatment segments for controlled release cardiovascular drugs include angina, hypertension, arrhythmias, cholesterol, and peripheral artery disease. Important growth factors for controlled release cardiovascular drugs include evolving patient demographics, environmental and lifestyle causative factors, increased public awareness of cardiovascular conditions and their associated morbidities, and expanded patient access to cardiovascular treatment services.
Highlights
- Analyzes and evaluates cardiovascular drugs formulated for controlled release and assesses the market potential for existing and potential future products
- Analyzes product technologies and product development factors
- Provides detailed assessments of key cardiovascular market segments, market demographics and business strategies
- Provides market data and forecasts to 2015
- Profiles market sector participant companies, their product development activities and strategies
|
|
|
|
